Announced details
Alleviation of the physical and psychological symptoms associated with PMS (premenstrual syndrome), as well as women’s well-being and femtech
Approximately 70%–80% of Japanese women are said to experience PMS.
The companies began joint research in May 2023 and have maintained a strategic partnership since 2023. They jointly filed a use patent covering the research results for KB-1.
A startup company originating from Hokkaido University, based in Sapporo, Hokkaido. Its operations range from the discovery of probiotic strains and functional evaluation to the manufacture and sale of food ingredients, as well as the manufacture and sale of research reagents and the provision of advanced analytical services. Its representative director and president is Murakami Mutsumi (村上睦).
Sapporo, Hokkaido (LAB社 headquarters)
The impact on the overall performance of our group for the current fiscal year is expected to be minor. We will actively develop this business as one of the new businesses under our Medium-Term Management Plan 2028.
The company does not address Contract Value / Offering price.
Ministry of Economy, Trade and Industry
| Item | Details |
|---|---|
| Names of Products / Services Covered | Probiotic strain “KB-1”, Supplements for people experiencing PMS |
| Counterparty | 株式会社LABバイオテック |
| Counterparty overview | A startup company originating from Hokkaido University, based in Sapporo, Hokkaido. Its operations range from the discovery of probiotic strains and functional evaluation to the manufacture and sale of food ingredients, as well as the manufacture and sale of research reagents and the provision of advanced analytical services. Its representative director and president is Murakami Mutsumi (村上睦). |
| Relationship with the Company | The companies began joint research in May 2023 and have maintained a strategic partnership since 2023. They jointly filed a use patent covering the research results for KB-1. |
| Launch date | Around the end of 2026 or early 2027 (planned start of sales) |
| Applicable area | Alleviation of the physical and psychological symptoms associated with PMS (premenstrual syndrome), as well as women’s well-being and femtech |
| Location | Sapporo, Hokkaido (LAB社 headquarters) |
| Quantitative Effects | Approximately 70%–80% of Japanese women are said to experience PMS. |
| Impact on Business Performance | The impact on the overall performance of our group for the current fiscal year is expected to be minor. We will actively develop this business as one of the new businesses under our Medium-Term Management Plan 2028. |
| Source | Ministry of Economy, Trade and Industry |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Joint research and human clinical trials produced useful and meaningful results showing that KB-1 converts soy isoflavones into the aglycone form, which has higher absorption and activity, thereby alleviating the physical and psychological symptoms associated with PMS.